Foresee Pharmaceuticals Reports Positive DSMB Review for Casppian Phase 3 CPP Trial February 4, 2026 by Mathieu Maurice Foresee Pharmaceuticals has announced that the independent Data and Safety Monitoring Board (DSMB) has completed its fourth safety review of the Casppian Phase 3 registration study and reported positive findings. …
